Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + abiraterone versus placebo + abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
2020-000346-33Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and prostate adenocarcinoma comparing Capivasertib + abiraterone acetate with Placebo + abiraterone acetate (2 arms). Primary endpoint: Radiographic progression-free survival. Started May 2020; status: active.
02
Drugs
capivasertibabiraterone
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on 2020-000346-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000346-33.